Analysis of Protein Biopharmaceuticals

Similar documents
Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia

Assessment of Active Biopharmaceutical Ingredients Prior To and Following Removal of Interfering Excipients

BIOPHARMACEUTICAL SERVICES

Assistant Professor Mohammad A Alsenaidy, MSc, PhD, Saudi Arabia

VICH Topic GL40. at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS

Technical Challenges in the Development of Biosimilars. E. Morrey Atkinson, PhD Interphex May 1, 2012

Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product ICH Guidance

FDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA

Chapter 6. Techniques of Protein and Nucleic Acid Purification

Development. - Be Your Partner-

ARBRE-P4EU Consensus Protein Quality Guidelines for Biophysical and Biochemical Studies Minimal information to provide

Molecular characterization, detection & quantitation of biological products Purin Charoensuksai, PhD

PHARMACEUTICAL TESTING

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.

Examples of regulatory expectations for analytical characterization and testing

Reference Standards: Overview and Strategy for Development to Commercialization

Fusion Analytical Method Validation

CASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011

The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives

Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences

HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT

Fusion Analytical Method Validation

The United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts

Challenges in peptide mapping mass spectrometry of biopharmaceuticals

Unified Workflow for Monoclonal Antibody Charge Heterogeneity, Purity, and Molecular Weight Analysis

Comparability assessment in the development of follow-on protein products: Case studies from Omnitrope

Impurity Control in the European Pharmacopoeia

Analytical Methods Development and Validation

An Industry Perspective on Established Conditions in the Analytical Control System. Christof Finkler, F. Hoffmann-La Roche

Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations

Archived Content. This content was archived on June 24, 2013.

QBD BIOLOGICS: REGULATORY PERSPECTIVE. 8Jun2015 Mark Alasandro

Antibody-Drug Conjugate Characterization and Quality Assurance

Application Note # ET-20 BioPharma Compass: A fully Automated Solution for Characterization and QC of Intact and Digested Proteins

An FDA Perspective on the Implementation of State-of-the-Art Analytical Methods for the Development of Therapeutic Proteins

Making the Transition to CE Methods and between CE Methods- An FDA Reviewer s Perspective

Stability of Biological Products

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM

Capillary Electrophoresis Compendial Applications

Biochromatography Bring more Zen into your life and laboratory

Analytical similarity: Lessons from the first US biosimilar

Proteomics And Cancer Biomarker Discovery. Dr. Zahid Khan Institute of chemical Sciences (ICS) University of Peshawar. Overview. Cancer.

Supplementary Figure 1. Detailed piping and instrumentation diagram (P&ID) for the InSCyT system. Nature Biotechnology: doi: /nbt.

Regulatory Considerations on. Office of Biotechnology Products

Lecture 5: 8/31. CHAPTER 5 Techniques in Protein Biochemistry

Regulatory Perspectives on Higher Order Structure Evaluations for Protein Products. Emily Shacter, Ph.D.

Chapter 5: Proteins: Primary Structure

Comparability to establish Biosimilarity

Vaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study.

Regulatory Consideration for the Characterization of HOS in Biotechnology Products

Subject Index. chromatography step, 125-

Automated and quantitative analysis of biologics

Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus

Develop A Highly Similar" Biosimilar Compound: Lessons Learnt

Biotechpharma company profile. Romanas Ramanauskas Business development manager

Subject Index. See for options on how to legitimately share published articles.

Purification: Step 1. Lecture 11 Protein and Peptide Chemistry. Cells: Break them open! Crude Extract

Purification: Step 1. Protein and Peptide Chemistry. Lecture 11. Big Problem: Crude extract is not the natural environment. Cells: Break them open!

Size Exclusion Chromatography of Biosimilar and Innovator Insulin Using the Agilent AdvanceBio SEC column

Monoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column

Advanced QA/QC characterization MS in QC : Multi Attribute Method

Chapter 9 Quality Control Biochemistry

Chapter 9 Quality Control Biochemistry

Thermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis

Validation of a Dual Wavelength Size Exclusion HPLC Method with Improved Sensitivity to Detect Aggregates of a Monoclonal Antibody Biotherapeutic

Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products

High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography

Capillary Electrophoresis of Proteins

Separation of Native Monoclonal Antibodies and Identification of Charge Variants:

Laboratory Services Alcami s comprehensive development and testing services are well established and ready to assist your pharmaceutical product

Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3

Proteomics. Proteomics is the study of all proteins within organism. Challenges

The new innovations of mab biolimilars and antibody therapeutics Our dedication to human health

Kevin D. Altria. Analysis of Pharmaceuticals by Capillary Electrophoresis

Chromatographic Workflows for Biopharmaceutical Characterization

Kinetics Review. Tonight at 7 PM Phys 204 We will do two problems on the board (additional ones than in the problem sets)

LIFE SCIENCES LABORATORY SERVICES

ANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES

Executive Summary. clinical supply services

Tony Mire-Sluis Vice President, Corporate, Product and Device Quality Amgen Inc

EXTRACTABLE & LEACHABLES SERVICES

HPLC 2016 Short Courses

Streamlined and Complete LC-MS Workflow for MAM

Impurities from degradation of Drug Substances

Intertek Pharmaceutical Services Laboratory & Assurance Solutions. Pharmaceutical Services

Downstream Processing (DSP): Microscale Automation of Biopharmaceutical Processes. Michel Eppink, Synthon BV, Nijmegen, The Netherlands

EAG.COM MATERIALS SCIENCES APPLICATION NOTE. By J. Tompkins 1, T. Spurgeon 1, R. Tobias 1, J. Anders 1, E. Butler-Roberts 2, and M.

An FDA perspective on the implementation of state-of-the-art analytical methods for therapeutic proteins

Simple, Robust, High Quality Intact Mass Analysis A Biosimilars Case Study

Capillary Electrophoresis in Quality Control PART II: CE-SDS: Method Development and Robustness

Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective

3D Structure of Biologics in a Convenient Immunoassay Format

A Regulatory Perspective on Characterization and Control of Process-Related Impurities

Isolation of Protein

Laboratory Reagents. for life science research.

Your bridge to. better medicines

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Modern Analytics for Biologics: Platforms, Multi-Attribute Methods and Real-Time Release

Regulatory Perspective on Analytical Method Validation During Product Development

ALP (alkaline phosphatase) calibrators were analyzed manually in microtiter plates to find the linearity range by following this protocol:

Transcription:

Analysis of Protein Biopharmaceuticals Comprehensive cgmp Services at Every Stage of Drug Development Amazing where you can go

At Solvias, we work closely with you Solvias provides comprehensive services for protein-based drugs, to biotechnology and pharmaceutical companies, at every stage of drug development. to design customized programs Solvias can help you to solve your most complex analytical challenges by providing expert guidance and by designing flexible and customized programs. Complex projects are coordinated by dedicated professional customer project managers. that meet your needs validation program is performed under cgmp according to ICH guidelines and typically includes the following parameters: specificity and selectivity, accuracy and precision, limit of detection (LOD) / limit of quantification (LOQ), linearity and measurement range, robustness, and solution stability. A milestone-based program can easily be designed and adapted to best fit the needs of your drug development program. All product-specific intellectual property (IP) for methods developed by Solvias is assigned to the customer. and are tailored to your drug. Methods destined for use in pharmaceutical release testing are developed with a focus on robustness and reproducibility. The goal of the method development program is to establish a reliable method and carefully describe it in a standard operating procedure (SOP) that can readily be executed at Solvias or transferred to your laboratory of choice. Within the framework of the method development program, critical parameters such as the linearity, reproducibility, and LOQ will be checked to ensure reliable analytical results. A written SOP that includes product specifications is a prerequisite for beginning a method validation program. The method The selection of the techniques to be used is based upon the properties of the drug. For example, to establish a stability-indicating method, techniques such as CE and HPLC are applied to samples that have been stressed (e.g. temperature). As both are orthogonal methods with different separation processes, they reveal a complementary picture of product-related degradation forms. The optimal method can then be further developed. We preferentially apply quantitative methods, if quantification is desired (e.g. capillary electrophoresis instead of flat bed electrophoresis).

Technology base A broad range of capabilities allows Solvias to apply the best solution to your problem Capillary electrophoresis (CZE, CE-IEF, CE-SDS; UV and LIF detection) Chromatography (HPLC, GC, DC, SEC, IEC; many special detectors) Electrophoresis (IEF, SDS-PAGE, native gel; standardized and ready gels) Amino acid analysis Mass spectrometry (ESI, MALDI-TOF/TOF-MS) Western blotting ELISA, ILA Hyphenated techniques (LC-MS) Quantitative PCR, threshold system Spectroscopy (UV/VIS, CD, fluorescence) Analytical ultracentrifugation Light scattering (MALS, DLS) DNA sequencing (cgmp) Analysis of Protein Biopharmaceuticals

Applications Complete characterization programs according to ICH Guideline Q6B: comprehensiveness is our strength Structural characterization Amino acid sequence Amino acid composition Terminal amino acid sequence Peptide map Sulfhydryl groups and disulfide bridges Monosacchoride analysis Carbohydrate structure Spectroscopy Purity Determination of molecular entities composing the drug substance Physicochemical properties Molecular weight Molecular size Isoform pattern Isoelectric point Extinction coefficient Electrophoretic patterns Liquid chromatographic patterns Spectral properties Glycan analysis PEG analysis Process-related impurities Residual solvents Leachables (e.g. ligands for affinity chromatography) Cell media components (e.g. growth hormones) Residual DNA Residual host cell protein Detergents Buffer/matrix composition (anion, cation, Tween ) Residual water (Karl Fischer) Quantity A 280 Quantitative amino acid analysis Nitrogen determination Proteinassay (Lowry) Immunoassay (ELISA) Product-related impurities Degradation Aggregation (dimers, higher oligomers and aggregates) Protein oxidation Protein deamidation Disulfide scrambling Expipiants All classes of molecule Contaminants Microbial contamination Endotoxin Virus contamination Heavy metals

Practical solutions to complex problems Solvias brings years of pharmaceutical experience to solve the most complex analytical and regulatory challenges Peptide mapping by LC-MS Disulfide bridging by LC-MS Determination of oxidative forms by e.g. LC-MS and LC-UV Isoelectric focusing by capillary electrophoresis PEG substitution by capillary electrophoresis and mass spectrometry Carbohydrate analysis by e.g. HPLC and capillary electrophoresis HPAEC-Dionex, MALDI-TOF/TOF mass spectrometry Content determination by amino acid analysis Determination of extinction coefficient by amino acid analysis and UV/VIS absorbance Quantification of Tween

We focus on reliable and efficient methods for pharmaceutical release testing Disulfide bridging Enzymatic cleavage of the native protein LC-MS separation and identification of peptide fragments Proof of proper folding by presence of species with proper disulfide bridging and absence of improperly bridged fragments Reductive alkylation to induce shift of bridged peptides in the chromatogram as a control step Separation of protein pl markers by CE-IEF Carbohydrate analysis in release testing Sialic acid by HPLC Neutral sugars by HPLC Glycosylation with and without sialic acid by capillary electrophoresis HPAEC-PAD Biosimilar/Follow-on Biologics Comprehensive choice of state-of-the-art methodology Experience to ensure successful registration Dedicated project management Plot of the isoelectric point versus migration time obtained by CE-IEF Cf. our publication: Application of capillary zone electrophoresis and reversed-phase high-performance liquid chromatography in the biopharmaceutical industry for the quantitative analysis of the monosaccharides released from a highly glycosylated therapeutic protein, K. Racaityté, ˇ S. Kiessig and F. Kálmán (Solvias AG): Journal of Chromatography A, Volume 1079, Issues 1 2, 24 June 2005, pages 354 365.

Services Bioanalytical programs individually tailored to meet your needs Solvias provides comprehensive physical chemistry services for the identification and selection of polymorphs, salts, and co-crystals, including method development for polymorphic purity and the optimization of crystallization processes. With years of drug development experience as a former research group of a major pharmaceutical company, we can help you crystallize your ideas. Primary activities Characterization (for regulatory submission) Method development and validation (ICH) QC Release testing (cgmp) Stability studies (cgmp) Comparability Quality FDA-inspected cgmp contract laboratory approved by Swissmedic ISO 9001-certified QM system Additional services include Certification, storage and supply of customer-specific reference substances Analytical support in process validation Analytical support in formulation development Extractables and leachables Analytical troubleshooting

Solvias AG Römerpark 2 4303 Kaiseraugst Switzerland Tel. +41 61 845 60 00 Fax +41 61 845 69 00 info@solvias.com www.solvias.com 1008.21.2e